This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Dublin, March 15, 2018 (GLOBE NEWSWIRE) -- The "Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market ...
An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.
The report on Uveitis clinical trials highlights opportunities in understanding trial count, enrollment trends, and successful trial regions. It aids strategic investment decisions by identifying key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback